Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts

(antibody/breast carcinoma)

Sally J. DeNardo*†, David L. Kukis*, Linda A. Kroger*, Robert T. O'Donnell*‡, Kathleen R. Lamborn§, Laird A. Miers*, David G. DeNardo*, Claude F. Meares¶, and Gerald L. DeNardo*

*Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA 95816; ‡Veterans Administration of Northern California Health Care System; §Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143; and ¶Department of Chemistry, University of California, Davis, CA 95616

ABSTRACT   Synergistic multimodality therapy is needed for breast cancer. Breast cancer frequently has p53 mutations that result in cells less likely to undergo apoptosis when exposed to DNA damaging therapies. Taxol (paclitaxel) is more effective in the presence of mutant p53. ^{90}Y-labeled DOTA-peptide-ChL6 (^{90}Y-ChL6, where ChL6 is chimeric L6 antibody and DOTA is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid) is a novel radioimmunoconjugate for targeting radiation to cancer. It has a stable metal chelator and a peptide linker that can be catabolized by hepatic lysozymes. This study was designed to assess potential synergism between Taxol and ^{90}Y-ChL6 in a highly anaplastic breast cancer model, HBT 3477. There was no tumor response in mice receiving ChL6 or Taxol alone. In mice receiving ^{90}Y-ChL6 alone, 79% (15 of 19) of tumors responded although none were cured. If Taxol was administered 24–72 hours before ^{90}Y-ChL6, again, 79% (23 of 29) of tumors responded but 21% were cured. When Taxol was administered 6 or 24 hours after ^{90}Y-ChL6, 100% (46 of 46) of tumors responded and 48% were cured. Taxol given with ^{90}Y-ChL6 did not substantially increase toxicity. Enhancement of the therapeutic effect when Taxol was added to ^{90}Y-ChL6 therapy for HBT 3477 xenografts was striking. The synergistic therapeutic effect of Taxol with ^{90}Y-ChL6 may relate to the p53 mutant status and *BCL2* expression in HBT 3477 cells, observations that increase the likelihood that the results of this study are relevant to therapy for breast cancer in patients. In conclusion, Taxol seemed to be synergistic with ^{90}Y-ChL6 in this human breast cancer model. Up to 50% of these anaplastic breast cancer xenografts were cured by combined modality therapy.

Novel, synergistic, multimodality therapy is needed for breast cancer to combat the molecular mechanisms, genetic mutations, and epigenetic abnormalities that protect the cancer from therapeutic interventions. Breast cancer frequently has p53 mutations and produces Bcl2 protein that result in cells less likely to undergo apoptosis when exposed to DNA damaging therapies, such as chemotherapy or radiotherapy (1–5). Hypoxia and dysregulation of cellular oncogenes further select for survival and growth of cancer cell mutants (1–4). Because metastatic breast cancer is currently incurable with standard multimodality therapy, novel strategies are necessary (6). Radioimmunotherapy, a systemic targeted radiation modality,

damages tumor DNA while maintaining a high therapeutic index (7, 8). Studies in patients with advanced resistant breast cancer showed cancer responses (9, 10) that warrant combinations of this modality with other agents that enhance apoptosis.

^{131}I-labeled ChL6 radioimmunotherapy has induced significant, albeit temporary, therapeutic responses in patients with incurable, metastatic breast cancer (9, 10). Studies in a human breast cancer xenograft model of the novel radioimmunoconjugate, ^{90}Y-labeled DOTA-peptide-ChL6 (^{90}Y-ChL6, where ChL6 is chimeric L6 antibody and DOTA is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid) showed that most tumors responded to 9.6 MBq of ^{90}Y-ChL6, but tumors were not cured (11, 12). ^{90}Y-ChL6 has an exceptionally stable ^{90}Y chelate and a biodegradable linker that reduce radiation to normal tissues.

The role of p53 in monitoring DNA damage is now well established, in part by the inability of cells lacking functional p53 to arrest in G_1 phase after DNA damage (1, 2). G1 arrest provides time for DNA repair to maintain chromosomal fidelity and to promote survival of normal cells (1–4). Increased resistance to radiation and other DNA damaging agents has usually been observed in p53 null or mutated cells (1–4). However, both p53-dependent and p53-independent cell deaths are inhibited by *BCL2* (13).

Taxol (paclitaxel) has been shown to have efficacy in ovarian and breast cancers because it stabilizes microtubule formation resulting in mitotic block, *BCL2* disfunction, and activation of apoptosis (14–17). Taxol is more effective in the presence of mutant p53 (2, 14). The study reported herein was designed to determine the potential for synergistic effects of Taxol and ^{90}Y-ChL6 on human breast cancer with mutant p53 protein expression. Because sequence, timing, and dose of these agents could be critical for synergism, a modified response surface approach was used to evaluate the therapeutic combination.

MATERIALS AND METHODS

Reagents. Carrier-free ^{90}Y (Pacific Northwest National Laboratory, Richland, WA) was purchased as chloride in 0.05 M HCl. Human-use-grade chimeric L6 (ChL6; Bristol–Myers Squibb Pharmaceutical Research Institute, Seattle), an antibody chimera consisting of a human IgG$_1$ constant region and the Fab' region of murine mAb L6 was used for the radioimmunoconjugate (18). ChL6 reacts with an integral membrane glycoprotein highly expressed on human breast, colon, ovary,

Abbreviations: DOTA, 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid; ChL6, chimeric L6 antibody; ^{90}Y-ChL6, ^{90}Y-labeled DOTA-peptide-ChL6.
†To whom reprint requests should be addressed at: 1508 Alhambra Boulevard, Suite 214, Sacramento, CA 95816.

Table 1. Tumor responses in HBT 3477 human breast cancer xenografts in mice

Treatment	No. tumors/no. mice	Initial tumor volume, mm^3 (range)	Mortality (<30 days)	No. tumor(s) PR	CR	C	Response rate, %
Control							
No treatment	17/10	82 (28–146)	1	3	0	0	18
ChL6 (315 μg)	16/8	160 (55–328)	1	0	0	2	13
Taxol (600 μg)	6/5	149 (55–250)	1	0	0	0	0
Taxol (300 μg)	6/4	187 (55–273)	0	0	0	0	0
ChL6 (315 μg) + Taxol (600 μg; +24 h)	12/7	141 (50–225)	2	3	0	0	25
^{90}Y-ChL6	19/10	100 (44–196)	0	12	3	0	79
^{90}Y-ChL6 + Taxol therapy							
^{90}Y-ChL6 + Taxol (600 μg; −72 h)	8/5	101 (39–182)	0	2	0	1	38
^{90}Y-ChL6 + Taxol (600 μg; −48 h)	4/3	146 (62–218)	1	2	0	1	75
^{90}Y-ChL6 + Taxol (300 μg; −24 h)	8/5	104 (62–164)	0	5	1	2	100
^{90}Y-ChL6 + Taxol (600 μg; −24 h)	9/5	146 (87–218)	0	7	0	2	100
^{90}Y-ChL6 + Taxol (300 μg; +6 h)	10/5	109 (44–187)	0	3	2	5	100
^{90}Y-ChL6 + Taxol (600 μg; +6 h)	18/10	112 (47–237)	0	5	5	8	100
^{90}Y-ChL6 + Taxol (600 μg; +24 h)	18/10	90 (33–187)	0	3	6	9	100

Response rate = cure (C) + complete regression (CR) + partial regression (PR). Control mice did not receive a combination of ^{90}Y-ChL6 and Taxol. ^{90}Y-ChL6 was always at 9.6 MBq.

and lung carcinomas (19, 20). Taxol (paclitaxel, Bristol–Myers Squibb), a natural product from the taxane group with antitumor activity and novel antimicrotubule properties, was obtained as a nonaqueous solution and diluted in 0.9% sodium chloride for injection. Mouse doses of 300 and 600 μg of Taxol were calculated to represent 37 and 75 mg/m^2 in human dose equivalents, if it is assumed that the mouse is a 20-g standard mouse (21). This is below the range of doses being used for treatment of women with metastatic breast cancer (range 135–250 mg/m^2) (22).

Cell Lines. HBT 3477, a human breast adenocarcinoma cell line, was obtained from Bristol–Myers Squibb Pharmaceutical Research Institute (Seattle). HBT 3477 tumors are aneuploid, with a DNA index of 1.5, and negative for estrogen and progesterone receptors by immunohistochemistry; greater than 70% of HBT 3477 cells stained with L6 in the type 1 pattern defined by Mattes *et al.* (23) (Prodex, Aeron Biotechnology, San Leandro, CA). p53 has been shown to be mutant, deleting the region detecting double-stranded DNA breaks, and *BCL2* expression is present (24).

^{90}Y-ChL6. ^{90}Y-ChL6 (^{90}Y-labeled DOTA-peptide-ChL6) was prepared by prelabeling the DOTA (1,4,7,10-tetraazacyclododecane-*N,N′,N″,N‴*-tetraacetic acid) chelate before generating the radioimmunoconjugate, as described (11, 25). By HPLC, TLC, and cellulose acetate electrophoresis, greater than 98% was ^{90}Y-ChL6, and less than 4% of ^{90}Y-ChL6 was aggregated in all preparations. Immunoreactivity of ^{90}Y-ChL6 by cell-binding RIA using the HBT 3477 breast adenocarcinoma cell line as described (11) showed 100% binding relative to unmodified ChL6.

Mouse Studies. Female athymic BALB/c *nu/nu* mice (Harlan Sprague–Dawley), 7–9 weeks of age, were maintained according to University of California animal care guidelines on


FIG. 1. Temporal course of untreated and treated HBT 3477 tumors in mice. The optimal combination of Taxol and ^{90}Y-ChL6 (600 μg of Taxol given 24 hours after ^{90}Y-ChL6) (□) showed dramatic tumor regression; comparable decreases were seen in all ^{90}Y-ChL6/Taxol groups. The group of mice receiving ^{90}Y-ChL6 alone (■) also showed marked tumor regression but the effect was not sustained. Tumors in mice receiving 315 μg of ChL6 (○), 600 μg of Taxol (△), or no treatment (●) grew without interruption.


FIG. 2. Cure rate of HBT 3477 tumors in mice. Mice received one dose of Taxol (300 or 600 μg) prior to (−72, −48, or −24 hours) or after (+6 or +24 hours) ^{90}Y-ChL6. Cure rate was much better when Taxol was given after ^{90}Y-ChL6; there was no difference in efficacy between 300 or 600 μg of Taxol with ^{90}Y-ChL6. No cures were observed after administration of ^{90}Y-ChL6 alone (A), 300 μg of Taxol alone (B), or 600 μg of Taxol alone (C).

a normal diet ad libitum and under pathogen-free conditions. Five mice were housed per cage. To minimize ambient radiation, bedding was changed daily for 1 week after treatment with ^{90}Y-ChL6, and twice weekly thereafter. HBT 3477 cells grown in Iscove's medium (GIBCO/BRL) were harvested in logarithmic phase; $2.5–5.0 \times 10^6$ cells were injected subcutaneously into both sides of the abdomen of each mouse. Studies were initiated 3 weeks after implantation, when tumors were 28–328 mm^3.

Treatment groups of 5–10 mice received one dose of Taxol i.p. (300 or 600 μg) prior to (−72, −48, or −24 hours) or after (+6 or +24 hours) 9.6 MBq (260 μCi) of ^{90}Y-ChL6 (315 μg) i.v. Control groups of tumored mice received 300 or 600 μg of Taxol, 9.6 MBq of ^{90}Y-ChL6, 315 μg of unmodified ChL6, 315 μg of ChL6 with 600 μg of Taxol (+24 hours), or no treatment (Table 1). Survival was monitored daily; mouse weight, tumor size, and blood counts were measured two or three times per week for 12 weeks after injection or until death. Tumors were measured with calipers in three orthogonal diameters three times per week. Tumor volume was calculated as described by the formula for hemiellipsoids (26).

Blood samples were collected from tail veins with 2-μl microcapillary pipets. Samples from mice within a dose group were pooled and diluted 1:200 in PBS (0.9% saline/10 mM sodium phosphate, pH 7.6) for red blood cell counts, diluted 1:100 in 1% ammonium oxalate for platelet counts, or diluted 1:20 in 3% (wt/vol) acetic acid for white blood cell counts (27).

Tumoricidal Effect. Initial tumor volume was defined as the volume on the day before treatment. Mean tumor volume was calculated for each group on each day of measurement; tumors that had completely regressed were considered to have a volume of zero. Tumor responses were categorized as follows: C, cure (tumor disappeared and did not regrow by the end of the 84-day study); CR, complete regression (tumor disappeared for at least 7 days, but later regrew); PR, partial regression (tumor volume decreased by 50% or more for at least 7 days then regrew).

Statistical Analysis. Comparisons of response among treatment groups were done by the method of Cochran–Mantel–Haensel (28). The test generates a P value that indicates whether the observed differences in response among treatment groups may be due to chance. A ranking based on the quality of the response was assigned, ordered as C, CR, PR, and no response. To minimize the possibility of declaring the therapy effective when it was not, statistical testing was done in the following order. (*i*) A test was done to determine whether chance alone could explain observed differences among all groups. (*ii*) A test was done to see whether chance alone could explain any differences among the control groups, defined as those not receiving combined ^{90}Y-ChL6 and Taxol therapy. (*iii*) Comparison was made among the groups receiving different combinations of ^{90}Y-ChL6 and Taxol therapy. On the basis of statistically significant differences in the aforementioned comparisons, more specific comparisons were then performed between selected groups.

RESULTS

Tumoricidal Effect. Tumors in mice treated with Taxol alone (300 or 600 μg), unmodified ChL6 alone, unmodified

FIG. 3. White blood cell, platelet, and red blood cell counts in mice. Myelotoxicity was lesser in extent and duration in the group receiving ^{90}Y-ChL6 alone than among groups that received ^{90}Y-ChL6 and Taxol. Addition of Taxol had a moderate but brief effect on white blood cell or red blood cell counts. ^{90}Y-ChL6, ×; 300 μg of Taxol, ▲; 600 μg of Taxol, △; 300 μg of Taxol given 24 hours before ^{90}Y-ChL6, ●; 600 μg of Taxol given 24 hours before ^{90}Y-ChL6, ○; 600 μg of Taxol given 6 hours after ^{90}Y-ChL6, ■; 600 μg of Taxol given 24 hours after ^{90}Y-ChL6, □.

ChL6 with Taxol, or untreated grew without interruption, whereas those treated with a combination of ^{90}Y-ChL6 and Taxol showed a dramatic decrease in volume (Fig. 1). Groups were analyzed as described using the Cochran–Mantel–Haensel method to determine whether observed differences in response could be due to chance. Six groups (76 tumors) that did not receive combined ^{90}Y-ChL6 and Taxol were used to assess control responses (Table 1). Only the group that received ^{90}Y-ChL6 alone differed significantly ($P = 0.001$) when compared with the untreated control group; all other groups used to assess control responses were not different from the untreated control or from each other ($P > 0.28$). Among groups of mice receiving no ^{90}Y-ChL6, the response rates, generally partial regressions, ranged from 0 to 25% (Table 1). In mice receiving 9.6 MBq of ^{90}Y-ChL6 alone, 79% (15 of 19) of tumors achieved a response although none were cured (Fig. 2).

Seven groups of mice received combined ^{90}Y-ChL6 and Taxol therapy. In mice receiving combined ^{90}Y-ChL6 and Taxol therapy where Taxol (300 or 600 μg) was administered before ^{90}Y-ChL6 (-72, -48, or -24 hours), 79% (23 of 29) of tumors responded and 21% (6 of 29) were cured. When Taxol (300 or 600 μg) was administered after ^{90}Y-ChL6 ($+6$ or $+24$ hours), 100% (46 of 46) of tumors achieved a response and 48% (22 of 46) were cured (Fig. 2). The overall evaluation of these combined treatment groups showed significant differences among them ($P = 0.003$). Specific analysis of the five groups that received 600 μg of Taxol and ^{90}Y-ChL6 also showed significant differences in response ($P = 0.002$). Further analysis of the 600-μg groups, comparing Taxol given before versus after ^{90}Y-ChL6, revealed a significant difference ($P = 0.001$); mice treated with Taxol after ^{90}Y-ChL6 had greater reduction in tumor volume than those where Taxol was given before ^{90}Y-ChL6. There was no statistical difference between the response of tumors in mice receiving 300 μg versus 600 μg of Taxol.

Weight Loss. Groups of mice receiving no ^{90}Y-ChL6 showed no weight loss. Mice that received only ^{90}Y-ChL6 lost 15% of their initial body weight but began to regain weight by day 12 after therapy. All groups receiving ^{90}Y-ChL6 and Taxol demonstrated similar transient weight loss (3–16% of initial body weight) and subsequent weight gain.

Myelotoxicity. Blood counts remained stable in the untreated control group. There was a moderate but brief decrease in white blood cell and platelet counts among control groups that received only Taxol (Fig. 3). Myelotoxicity was lesser in extent and duration in the group receiving ^{90}Y-ChL6 alone than among groups that received ^{90}Y-ChL6 and Taxol. In all groups, the platelet count began to recover after 14 days; the white blood cell count began to recover after 21 days; red blood cell counts declined less and began to recover after 21 days.

Mortality. Six mice died within 30 days of therapy; five of the deaths were in control groups that received no ^{90}Y-ChL6 (Table 1). The deaths were randomly distributed [Fisher's Exact test, $P = 0.2$ (29)] among the groups.

DISCUSSION

The intent of this study was to examine the potential of Taxol as a synergistic agent with ^{90}Y-ChL6 for therapy of breast cancer. Using the concept of a response surface model, a series of experiments were performed to evaluate the optimal dose and timing of Taxol relative to ^{90}Y-ChL6. The results of each experiment in this series were evaluated to determine parameters for the next experiment in an effort to find the combination of variables likely to produce the best therapeutic effect. The experiments were not designed to prove one regimen statistically better than all others but to assure that the regimen selected was not substantially worse than the optimal and to

determine whether any regimen showed sufficient promise for future work (30, 31). ChL6 was chosen for the radioimmunoconjugate because ChL6 stained 75% of cancer cells in 48% of patients with metastatic breast cancers when tested by immunopathology (32). ChL6 also reacts with the majority of cells in HBT 3477 tumors grown subcutaneously in nude mice (11).

Enhancement of therapeutic effect when Taxol was added to ^{90}Y-ChL6 therapy for HBT 3477 xenografts was striking (Table 1). When Taxol was administered 6 or 24 hours after ^{90}Y-ChL6, 100% (46 of 46) of tumors responded and 48% (22 of 46) were cured. These results were better than when Taxol was given prior to ^{90}Y-ChL6 ($P = 0.001$; Fig. 2). There was no statistically significant therapeutic enhancement when 600 μg of Taxol was given versus 300 μg. No therapeutic response to Taxol alone was demonstrated in the HBT 3477 mouse model. When Taxol was given 24 hours after ChL6 without ^{90}Y, only 25% (3 of 12) of tumors achieved partial regression and there were no complete regressions or cures, thereby demonstrating that tumor-targeted radiation was essential for optimal therapeutic efficacy of ^{90}Y-ChL6/Taxol. Information from previous studies of tumor uptake indicate that 9.6 MBq of ^{90}Y-ChL6 delivers a radiation dose of 26.3–41.4 Gy to tumors (12).

The synergistic therapeutic effect of Taxol with ^{90}Y-ChL6 may relate in part to the *p53* mutant status and *BCL2* expression in HBT 3477 cells, observations that increase the likelihood that the results of our study are relevant to therapy for breast cancer in patients. Mutant *p53* and *BCL2* expression have been increasingly associated with breast cancer in patients (1, 4, 5). *p53* monitors DNA damage and interrupts cells in G_1 phase, providing time for their repair. Cells lacking functional p53 fail to pause in G_1 phase after DNA damage, are resistant to death from DNA damaging agents, and are frequently unable to initiate apoptotic cell death (1–3). Both *p53*-dependent and *p53*-independent apoptosis are inhibited by BCL2 (2, 13). Taxol induces G_2/M arrest and blocks BCL2 by phosphorylation followed by *p53*-independent apoptosis, and cells lacking functional *p53* are more sensitive to Taxol-induced G_2/M block (2, 14, 15, 17). We propose that the mechanisms enabling the ^{90}Y-ChL6/Taxol combination to be synergistic involve (*i*) death of *p53* mutant cancer cells through Taxol blockage of BCL2 and induction of *p53*-independent apoptosis, which is enhanced by ^{90}Y; and (*ii*) death of wild-type *p53* cancer cells due to radiation-induced DNA damage further enhanced by Taxol (33–35). Normal cells receive much lower doses of radiation than the cancer cells; at these low doses of radiation and Taxol, sublethal DNA damage can be repaired.

The goal of cancer therapy is to spare normal cells while damaging cancer cells sufficiently so that cells not killed outright undergo apoptosis. This goal has not been achieved because standard cytotoxic agents cause excessive toxicity to normal tissues. Our results suggest that the previously demonstrated therapeutic efficacy of ^{90}Y-ChL6 alone in a mouse model of breast cancer can be significantly enhanced by low doses of Taxol given after ^{90}Y has substantially cleared from normal tissues, thereby limiting toxicity.

In conclusion, ^{90}Y-ChL6 and Taxol can be given in a sequence that enhances therapeutic efficacy. Over time after injection, ^{90}Y-ChL6 binds to malignant cells as it circulates and unbound ^{90}Y-ChL6 is cleared from normal tissues. Thus, a "window" in time exists when there is ongoing tumor irradiation but little concurrent normal tissue irradiation. Given in this window, Taxol, a small molecule rapidly taken up by the cancer, enhanced the therapeutic effect of ^{90}Y-ChL6 on targeted malignant cells. The optimal time for Taxol administration in this xenograft model was 6–24 hours after ^{90}Y-ChL6. The HBT 3477 cells used in this study are relatively radioresistant, possess a *p53* mutation resulting in a nonfunctional protein, express *BCL2*, and are highly anaplastic. Such properties are frequently present in human breast cancer that is currently incurable by standard therapies. The therapeutic

response of aggressive HBT 3477 tumors to Taxol and ^{90}Y-ChL6 warrants studies of these agents in other models and in patients.

1. Levine, A. J., Momand, J. & Finlay, C. A. (1991) *Nature (London)* **351,** 453–456.
2. Harris, C. C. (1996) *J. Natl. Cancer Inst.* **88,** 1442–1455.
3. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C. C. (1991) *Science* **253,** 49–53.
4. Lane, D. P. (1992) *Nature (London)* **358,** 15–16.
5. Leek, R. D., Kaklamanis, L., Pezzella, F., Gatter, K. C. & Harris, A. L. (1994) *Br. J. Cancer* **69,** 135–139.
6. Parker, S. L., Tong, T., Bolden, S. & Wingo, P. A. (1996) *CA-Cancer J. Clin.* **65,** 5–27.
7. Wilder, R. B., DeNardo, G. L. & DeNardo, S. J. (1996) *J. Clin. Oncol.* **14,** 1383–1400.
8. DeNardo, S. J., O'Grady, L. F., Macey, D. J., Kroger, L. A., DeNardo, G. L., Lamborn, K. R., Levy, N. B., Mills, S. L., Hellström, I. & Hellström, K. E. (1991) *Nucl. Med. Biol.* **18,** 621–631.
9. DeNardo, S. J., Mirick, G. R., Kroger, L. A., O'Grady, L. F., Erickson, K. L., Yuan, A., Lamborn, K. R., Hellström, I., Hellström, K. E. & DeNardo, G. L. (1994) *Cancer* **73,** 1023–1032.
10. DeNardo, S. J., O'Grady, L. F., Richman, C. M. & DeNardo, G. L. (1994) in *Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment*, ed. Ceriani, R. L. (Plenum, New York), pp. 203–211.
11. DeNardo, S. J., Zhong, G.-R., Salako, Q., Li, M., DeNardo, G. L. & Meares, C. F. (1995) *J. Nucl. Med.* **36,** 829–836.
12. DeNardo, S. J., Gumerlock, P. H., Winthrop, M. D., Mack, P. C., Chi, S. G., Lamborn, K. R., Shen, S., Miers, L. A., deVere White, R. W. & DeNardo, G. L. (1995) *Cancer Res.* **55,** 5837–5841.
13. Strasser, A., Harris, A. W., Jacks, T. & Cory, S. (1994) *Cell* **79,** 329–339.
14. Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y. F., Foster, S. A., Demers, G. W. & Galloway, D. A. (1996) *Nat. Med.* **2,** 72–79.
15. Vogelstein, G. (1990) *Nature (London)* **348,** 681–682.
16. Horwitz, S. B. (1992) *Trends Pharmacol. Sci.* **13,** 134–136.
17. Hadler, S., Chintapalli, J. & Croce, C. M. (1996) *Cancer Res.* **56,** 1253–1255.
18. Liu, A. Y., Robinson, R. R., Hellström, K. E., Murray, E. D., Chang, C. P. & Hellström, I. (1987) *Proc. Natl. Acad. Sci. USA* **84,** 3439–3443.
19. Hellström, I., Horn, D., Linsley, P., Brown, J. P., Brankovan, V. & Hellström, K. E. (1986) *Cancer Res.* **46,** 3917–3923.
20. Marken, J. S., Bajorath, J., Edwards, C. P., Farr, A. G., Schieven, G. L. Hellström, I., Hellström, K. E. & Aruffo, A. (1994) *J. Biol. Chem.* **269,** 7397–7401.
21. Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H. & Skipper, H. E. (1966) *Cancer Chemother. Rep.* **50,** 219–244.
22. Hortobagyi, G. N. & Holmes, F. A. (1996) *Semin. Oncol.* **23,** 4–9.
23. Mattes, M. J., Major, P. P., Goldenberg, D. M., Dion, A. S., Hunter, R. V. P. & Klein, K. M. (1990) *Cancer Res.* **50,** 880–884.
24. Winthrop, M. D., DeNardo, S. J., Muenzer, J. T., Chi, S. G. & Gumerlock, P. H. (1997) *Cancer*, in press.
25. Li, A., Meares, C. F., Salako, Q., Kukis, D. L., Zhong, G.-R., Miers, L. A. & DeNardo, S. J. (1995) *Cancer Res.* **55,** 5726s–5728s.
26. DeNardo, G. L., Kukis, D. L., Shen, S., Mausner, L. F., Meares, C. F., Srivastava, S. C., Miers, L. A. & DeNardo, S. J. (1996) *Clin. Cancer Res.*, **3,** 71–79.
27. Seiverd, C. (1972) *Hematology for Medical Technologists*, (Lea Febiger, Philadelphia), 4th Ed., pp. 91–432.
28. Agresti, A. (1990) *Categorical Data Analysis* (Wiley, New York), pp. 283–287.
29. Agresti, A. (1990) *Categorical Data Analysis* (Wiley, New York), p. 60.
30. Carter, W. H., Jr., & Wampler, G. L. (1986) *Cancer Treat. Rep.* **70,** 133–140.
31. Berenbaum, M. C. (1990) *Br. J. Cancer* **61,** 101–109.
32. Howell, L. P., DeNardo, S. J., Levy, N. B., Lund, J. & DeNardo, G. L. (1995) *Int. J. Biol. Markers* **10,** 129–135.
33. Liebmann, J., Cook, J. A., Fisher, J., Teague, D. & Mitchell, J. B. (1994) *Int. J. Radiat. Oncol. Biol. Phys.* **29,** 559–564.
34. Minarik, L. & Hall, E. J. (1994) *Radiother. Oncol.* **32,** 124–128.
35. Balakrishna, L. L., Ferrell, S. M. & Block, N. L. (1995) *Anticancer Res.* **15,** 93–98.